BTIG Research Initiates Teva Pharmaceutical At Buy

Analysts at BTIG Research initiated coverage on Teva Pharmaceutical Industries Ltd (ADR) TEVA with a Buy rating. The target price for Teva Pharmaceutical is set to $77. Teva Pharmaceutical shares have gained 15.77 percent over the past 52 weeks, while the S&P 500 index has surged 5.35 percent in the same period. Teva Pharmaceutical's shares rose 0.60 percent to $62.01 in after-hours trading.